Class / Patent application number | Description | Number of patent applications / Date published |
514090000 | Chalcogen in the six-membered hetero ring | 32 |
20080200436 | Combination Comprising Zd6474 And An Antiandrogen - The present invention relates to a method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation, particularly a method for the treatment of a cancer, particularly a cancer involving a solid tumour, which comprises the administration of ZD6474 in combination with androgen ablation; to a pharmaceutical composition comprising ZD6474 and an antiandrogen; to a combination product comprising ZD6474 and an antiandrogen for use in a method of treatment of a human or animal body by therapy; to a kit comprising ZD6474 and an antiandrogen; to the use of ZD6474 and an antiandrogen in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal such as a human which is optionally being treated with ionising radiation. | 08-21-2008 |
20080242637 | Use of Cytochrome P450 Enzyme CYP2WI as a Drug Target for Cancer Therapy - The present invention relates to a novel drug target in cancer therapy. More closely it relates to use of the cytochrome P450 enzyme CYP2W1 and its promoter as a drug target for cancer therapy. It also relates to screening methods for obtaining therapeutic agents for cancer therapy and to therapeutic agents comprising moieties showing binding affinity for CYP2W1 and moieties with cytotoxic/anti-cancer effect. | 10-02-2008 |
20080242638 | INDUCTION OF DIFFERENTIAL STRESS RESISTANCE AND USES THEREOF - This invention relates to methods of inducing differential stress resistance in a subject with cancer by starving the subject for a short term, administering a cell growth inhibitor to the subject, or reducing the caloric or glucose intake by the subject. The induced differential stress resistance results in improved resistance to cytotoxicity in normal cells, which, in turn, reduces cytotoxic side-effects due to chemotherapy, as well as improved effectiveness of chemotherapeutic agents. | 10-02-2008 |
20080269172 | Lysine based compounds - The present invention provides lysine based compounds of the formula; | 10-30-2008 |
20090170813 | Hypophosphorous Acid Derivatives and their Therapeutical Applications - Hypophosphorous acid derivatives having Formula (I) wherein .M is a [C(R3,R4)]n1-C(E,COOR1,N(H,Z)) group, or an optionally substituted Ar—CH(COOR1,N(H,Z)) group, or an a, β, or a β, g-cyclic amino acid; .R | 07-02-2009 |
20090281063 | IONTOPHORETIC PREPARATION FOR TREATMENT OF BREAST CANCER AND/OR MASTITIS - The present invention is to provide means to treat breast cancer and/or mastitis by topically administering a non-steroidal antiinflammatory analgetic agent and/or an anticancer agent and allowing them efficiently to arrive into the mammary gland. The present invention provides an iontophoretic preparation for treating breast cancer and/or mastitis which contains a non-steroidal antiinflammatory analgetic agent and/or an anticancer agent as an active ingredient and has a donor to be applied on a nipple part for topical administration of the active ingredient from the nipple part to the mammary gland by application of electric potential. | 11-12-2009 |
20090318388 | METHOD OF ACTIVATION OF OXAZAPHOSPHORINES - The present invention provides a method of hydroxylating or oxidizing a compound of interest in a subject (e.g., a cytotoxic oxazaphosphorine prodrug), by administering the compound of interest to the subject; and concurrently administering the subject a metalloporphyrin in an amount effective to hydroxylate or oxidize the compound of interest in the subject. | 12-24-2009 |
20100029592 | DEUTERIUM-ENRICHED FOSAPREPITANT - The present application describes deuterium-enriched fosaprepitant, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 02-04-2010 |
20100087399 | USE OF 9-OXOACRIDINE-10-ACETIC ACID, SALTS AND ESTERS THEREOF IN COMBINATION THERAPY OF OVARIAN CANCER - The present invention provides novel methods of combination therapy of ovarian cancer, pharmaceutical kits and combinations of 9-oxoacridine-10-acetic acid and/or salts and/or esters thereof with one or more chemotherapeutic agents. The proposed combination therapy is useful in enhancing the action of chemotherapeutic agents and their proliferative activity on human ovarian cancer cells. | 04-08-2010 |
20100273743 | MORPHOLIN-4-IUM 4 METHOXYPHENYL (MORPHOLINO) PHOSPHINODITHIOATE (GYY4137) AS A NOVEL VASODILATOR AGENT - The invention is directed to a method of administering hydrogen sulfide (H | 10-28-2010 |
20110015157 | CYCLIC INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 - This invention relates to novel compounds of the Formula (I), (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih); (Ii); (Ij), (Ik), (II) pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11 β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of cortisol in a cell or the inhibition of the conversion of cortisone to cortisol in a cell. | 01-20-2011 |
20110092462 | USE OF HIGH-DOSE OXAZAPHOSPHORINE DRUGS FOR TREATING IMMUNE DISORDERS - This disclosure relates, at least in part, to methods of eliminating adverse immune reactions in a subject in need thereof including those associated with autoimmune diseases, allergic reactions and transplant rejection, including administration of a lymphocytotoxic non-myeloablative amount of a oxazaphosphorine drug to the subject. | 04-21-2011 |
20110130366 | FOSAPREPITANT DIMEGLUMINE INTERMEDIATE, NEUTRAL FOSAPREPITANT, AND AMORPHOUS FOSAPREPITANT DIMEGLUMINE AND PROCESSES FOR THEIR PREPARATIONS - The present invention generally relates to a process for the preparation of fosaprepitant dimeglumine intermediate and its use in the preparation of fosaprepitant dimeglumine; to a neutral form of fosaprepitant in a solid state and processes for the preparation thereof; and to a stable amorphous fosaprepitant dimeglumine, having a stability at temperatures of about 2° C. to about 8° C. and at a relative humidity below at least 60%; and a process for the preparation thereof. | 06-02-2011 |
20120010172 | NOVEL UREA AND THIOUREA DERIVATIVES - The present application discloses compounds of formula (I) wherein X is ═O, ═S, ═NH, ═NOH and ═NO-Me; A is —C(═O)—, —S(═O) | 01-12-2012 |
20120035136 | ANTISENSE ANTIVIRAL COMPOUNDS AND METHODS FOR TREATING A FILOVIRUS INFECTION - The present invention provides antisense antiviral compounds, compositions, and methods of their use and production, mainly for inhibiting the replication of viruses of the Filoviridae family, including Ebola and Marburg viruses. The compounds, compositions, and methods also relate to the treatment of viral infections in mammals including primates by Ebola and Marburg viruses. The antisense antiviral compounds include phosphorodiamidate morpholino oligonucleotides (PMOplus) having a nuclease resistant backbone, about 15-40 nucleotide bases, at least two but typically no more than half piperazine-containing intersubunit linkages, and a targeting sequence that is targeted against the AUG start site region of Ebola virus VP35, Ebola virus VP24, Marburg virus VP24, or Marburg virus NP, including combinations and mixtures thereof. | 02-09-2012 |
20120077782 | METHOD OF ACTIVATION OF OXAZAPHOSPHORINES - The present invention provides a method of hydroxylating or oxidizing a compound of interest in a subject (e.g., a cytotoxic oxazaphosphorine prodrug), by administering the compound of interest to the subject; and concurrently administering the subject a metalloporphyrin in an amount effective to hydroxylate or oxidize the compound of interest in the subject. | 03-29-2012 |
20120157413 | PHOSPHOROUS DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS - The present invention relates to novel phosphorous derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors. | 06-21-2012 |
20120220552 | (THIO)MORPHOLINE DERIVATIVES AS S1P MODULATORS - The present disclosure relates to (thio)morpholine derivatives of the formula (I) | 08-30-2012 |
20120225847 | SQUARIC ACID DERIVATIVES AS INHIBITORS OF THE NICOTINAMIDE - The present application discloses novel squaric acid derivatives of the formula A: from —C(═O)—, —S(═O) | 09-06-2012 |
20120245128 | RAPID DETECTION AND QUANTIFICATION OF MODIFICATION OF MEDICINAL COMPOUNDS AND DRUG RESISTANCE ACTIVITY - The present disclosure in general relates to methods, systems, and apparatus for identifying modification of a medicinal compound exposed to a sample for use in determining which treatment to provide to a subject in need thereof. | 09-27-2012 |
20130157983 | Compounds for Use in the Treatment of Cancer - Pharmaceutical compositions comprise a first compound of Formula I or a physiologically acceptable salt thereof, and a cyto-protective amount of a manganese chelate of N,N′-dipyridoxyl ethylenedianiine-N,N′-diacetic acid (MnPLED): | 06-20-2013 |
20130310344 | N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS - The present invention relates to compounds of Formula (I): and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds inhibit Bcl-2 and/or Bcl-X | 11-21-2013 |
20140005148 | STABLE LIQUID FORMULATIONS OF NITROGEN MUSTARDS | 01-02-2014 |
20140221316 | NO- AND H2S- RELEASING COMPOUNDS - This disclosure relates to novel compounds containing an H | 08-07-2014 |
20140357599 | NOVEL UREA AND THIOUREA DERIVATIVES - The present application discloses compounds of formula (I) wherein X is ═O, ═S, ═NH, ═NOH and ═NO-Me; A is —C(═O)—, —S(═O) | 12-04-2014 |
20150342969 | METHODS FOR TREATING VIRAL INFECTIONS USING HYDROGEN SULFIDE DONORS - Certain embodiments are directed to methods of treating respiratory infection by administering an H | 12-03-2015 |
20160058779 | METHODS FOR TREATING VIRAL INFECTIONS USING HYDROGEN SULFIDE DONORS - Certain embodiments are directed to methods of treating respiratory infection by administering an H | 03-03-2016 |
20160068556 | TARGETED NITROXIDE AGENTS - A compound having a structure of: | 03-10-2016 |
20160075727 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS - The present invention provides a compound of Formula I: | 03-17-2016 |
20160129022 | Hydrogen Sulphide Compounds - The application describes Hydrogen Sulphide (H | 05-12-2016 |
20160193166 | ANTICONVULSIVE PHARMACEUTICAL COMPOSITIONS | 07-07-2016 |
20190144477 | FOSAPREPITANT PHOSPHATE INTERMEDIATE AND PREPARATION METHOD THEREFOR | 05-16-2019 |